Skip to content
  • English
  • Business
  • Entertainment
  • National
  • Lifestyle
  • Education
Daily News India

Daily News India

Just another WordPress site

  • English
  • Business
  • Entertainment
  • National
  • Lifestyle
  • Education
  • Toggle search form
  • Magic Bus Is One of India’s Best Employers among Nation-Builders 2021 Recognised By the Great Place To Work® Institute Business
  • Marengo CIMS Hospital’s cardiac surgeon Dr. Dhaval Naik honoured with Gujarat Garima Award Lifestyle
  • Samagra Shiksha Nagaland and Vibha Spotlight Data-Driven Foundational Learning at Oxford Education
  • Chokepoint Economics: How the Strait of Hormuz Stoppage Reshapes Global Trade Business
  • Shashaank Somani reveals Somani Surfaces’ new experience showroom for veneer, laminates, plywood and hardware fittings Business
  • Elation Visas Strengthens Its Position as a Trusted Immigration Advisory in India Business
  • Farukh Khan’s Kare Foundation Group (USA) Launches Unique Project Mother, Will Open 100 Maternity Homes Press Release
  • SharpLight Technologies Enters India: Doctor-Led Global Aesthetics Platform Launches at CosdermIndia 2026 Business

DCGI approves Themis Medicare’s VIRALEX® for Covid-19 treatment

Posted on March 5, 2022 By

Enhances both innate & adaptive immunity and strengthens body’s immune response to viral infections

March 5: In a landmark development for the treatment of COVID-19, Themis Medicare Ltd. (Themis), a Pharmaceutical company headquartered in Mumbai with a legacy of over 50 years of making new treatment options available, announced the approval of its antiviral drug VIRALEX® by the Drug Controller General of India (DCGI). As per the results of a double-blind randomized controlled trials (RCT), the drug helps in early relief of the clinical symptoms in mild tomoderateCOVID-19 patients.

Viralex® has been found to be effective and well tolerated in mild to moderate COVID-19, in two Randomized Controlled Clinical Trials conducted on 499 Indian patients.

In line with the DCGI’s current approach for approval of medicines for the management of the ongoing pandemic, approval for VIRALEX® (Generic name: Inosinepranobex) is based on the results of the robust phase 2 and phase 3RCTs conducted in India, and the well-established safety profile of the drug.

As per the results of the Phase 3 Randomized, Double-blind, Placebo-controlled Trial, 80.17% of patients treated with VIRALEX® showed clinical improvement on day 6, which is significantly higher (p<0.001) from that in the controlled group.

(52.38%) among the mild to moderate non-hospitalized COVID-19 patients. Clinical Cure was also significantly higher in the VIRALEX® group as compared to that in the placebo group on day 6 of treatment. There was early improvement and cure from symptoms in patients who received VIRALEX®. This drug was well tolerated by the patients without any serious side effects. The study was conducted during the Delta wave of the pandemic.

Randomized, Double-Blind, Placebo-controlled, Multicentre Trial is considered as the clinical research methodology of the highest global standard for evaluating drugs against diseases. Themis is one of the few companies to submit data from a higher number of patients from RCTs for approval in management of COVID-19.

After detailed deliberation, the drug regulatory authority granted permission to manufacture and market this new drug for restricted emergency use of the drug as an add on therapy for treatment of mild and moderate COVID-19.

VIRALEX® would be available on the prescription.

Based on the promising study results, the drug appears to offer immense clinical benefit to the patients in the early stages of COVID-19, thus reducing the load on the healthcare system.

VIRALEX® is an immune modulatory agent with broad-spectrum antiviral properties. It enhances both innate & adaptive immunity and strengthens the body’s defence response to viral infections. In an invitro study initiated by Themis, it showed dose-dependent inhibition of viral replication against SARS-CoV-2 (COVID-19).

According to Themis, VIRALEX® will be manufactured at an EU-GMP-certified facility with the highest safety standards and stringent manufacturing protocols in place, and the medication will be available in the form of a 500 mg tablet at a much affordable price.

Speaking at the release, Dr. Sachin Patel, Managing Director & CEO of Themis Medicare Ltd. said, “Our endeavor has always been to develop medicines that benefit patients and make healthcare far, far more effective. Given the current scenario of grave health concerns and economic challenges surrounding COVID-19 in India, this is our effort to contribute to the well being of people of India”.

“Due to the frequently mutating trend of the virus, the uncertainties of the pandemic continue. We hope access to effective treatment such as VIRALEX® will offer a much-needed therapeutic solution, and if initiated early in the disease, it would reduce the load on the healthcare system.”

Commenting on the significance of this development, Dr. Ashok Swain, Head Clinical Development, congratulated the entire Themis Medicare Ltd. team for achieving an important milestone of adding this effective medicine with an established safety profile to address the unmet need in the management of the pandemic.

“VIRALEX® is a new ray of hope in these challenging times,” he said.

Dr Raja Dhar, eminent pulmonologist and Director and Head of Department of Pulmonology, C K Birla Hospitals, said “Inosine Pranobexisa drug which enhances host immunity (immune modulatory effect) and can affect viral RNA and hence inhibits growth of several viruses. Phase 3 Double blind RCTs are rarein COVID 19. I am heartened to hear that Themis Medicare has come up with such a trial, which shows early clinical response and shortened period of recovery when used in mild to moderate COVID19 cases. This drug, if successfully used in clinical practice would considerably reduce the burden on healthcare system.

Dr Dhar is also the current Chair of Training and Education Initiatives, Indian Chest Society, and Director of Research and Training, National Allergy Asthma Bronchitis Institute.

With a strong R&D backup, skilled domestic & export teams, and 4 state-of-the-art manufacturing sites, the endeavour at Themis has always been to support the medical fraternity with solutions for major unmet medical needs like VIRALEX® for COVID-19…and still counting!

About Themis Medicare Ltd

Themis Medicare was incorporated in 1969 as a joint venture partnership at Vapi. Today, it is one of the fastest growing pharma Company specializing in the development of complex molecules. With strong research focus on injectables, complex generic products and drug-delivery systems, the Company has evolved in to being a formidable layer in the complex generics space.

It has a diversified business model with presence across the B2B model and strong presence in domestic B2C market. The Company also has a significant export presence in the RoW geographies. The qualified and experienced Management team is complemented by highly skilled R&D workforce. The Company has three vertically integrated manufacturing facilities, of which two are focused on developing APIs–1 each involved in manufacturing Synthetic API and Fermentation based API, and 1 is involved in manufacturing of Finished Dosage Formulations. Themis offers products in various dosage forms in multiple therapeutics areas with leadership in Pain Management and Critical Care. The Company has a strategy to focus and grow its injectables portfolio and develop its NDDS presence.

For more details, please visit: www.themismedicare.com

Business Tags:Business

Post navigation

Previous Post: India’s F1 hopeful, Jehan Daruvala signs exclusive representation agreement with Meraki Sport & Entertainment Pvt. Ltd
Next Post: IFSCA’s officer becomes the first to acquire a passport displaying the famed address of GIFT city, Gandhinagar

Related Posts

  • Community Engagement is Essential to Promote Vaccination Business
  • Perfect Infraengineers to Offer Right Shares worth Rs. 1158 lakh, the issue closes on August 24, 2023 Business
  • eduVelocity Global: Overseas education consultancy guides students to best-fit universities abroad despite Covid-19 challenges Business
  • The Most Awaited Cricket Season Has Arrived! Business
  • Leading US Wig Brand Paula Young Makes A Grand Entry Into The Indian Market Business
  • Manakamna Group launches Home Square- A one-stop mall for all interior solutions need Business

Recent Posts

  • Pan IIT Alumni India Welcomes PM Modi’s Visit to IIT Kharagpur for Platinum Jubilee Celebrations
  • ‘Plast Pack 2026’ Begins with Bhoomi Pujan; Mega Plastic Industry Expo to Commence on November 27
  • The Ambiente Brings Luxury Handmade Rugs and Carpets Online to Homes Across India
  • ‘Mere Mahavir 3.1 – Mahavir Nirvana Katha’ Concludes on a Grand Spiritual Note at Bharat Mandapam
  • HydraSure’s Gen Z Team Turns GTA VI Launch Day Into a Giveaway – Planned and Live in 24 Hours

Recent Comments

  • Unknown on Participants Reap Rewards in Wellman’s 8-Week Digital Campaign: IPL Tickets, Autographed Virat Kohli Merchandise, and More!
  • Blum and Renowned Architects Unveil a Fusion of Artistry at ACETECH Mumbai 2023: A World of Innovation and Elegance Business
  • Gujarat’s First Robotic Hip and Knee Replacement Centre Unveiled at Nirali Hospital Health
  • SRV Hospitals and Lokmanya Hospital collaborate to launch a New Centre of Excellence in Robotic Orthopaedics Health
  • Women’s Contribution in 100 Years of RSS Highlighted at Mumbai Seminar on ‘Shatayu Sangh Aur Mahila Sahabhagita’ Lifestyle
  • India prepares for Jiu Jitsu revolution this November at India Open International Gi & No-Gi tournament Press Release
  • Second Edition of ET Tech X 2022 in Greater Noida Business
  • Foxtrot DMC: Transforming Travelling into Memorable Adventures Business
  • Forcas Studio Ltd planning to raise up to Rs. 37.44 crore from public issue; IPO opens August 19 #3 Business

Copyright © 2026 Daily News India.

Powered by PressBook News WordPress theme